Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study-Reference-Cited by-同舟云学术

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

Published:2020-10 Issue:10 Volume:2 Page:e603-e612
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Biran Noa,Ip Andrew,Ahn Jaeil,Go Ronaldo C,Wang Shuqi,Mathura Shivam,Sinclaire Brittany A,Bednarz Urszula,Marafelias Michael,Hansen Eric,Siegel David S,Goy Andre H,Pecora Andrew L,Sawczuk Ihor S,Koniaris Lauren S,Simwenyi Micky,Varga Daniel W,Tank Lisa K,Stein Aaron A,Allusson Valerie,Lin George S,Oser William F,Tuma Roman A,Reichman Joseph,Brusco Louis,Carpenter Kim L,Costanzo Eric J,Vivona Vincent,Goldberg Stuart L

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference25 articles.

1. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality;Zhang;Int J Antimicrob Agents,2020

2. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology;Channappanavar;Semin Immunopathol,2017

3. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome;Le;Oncologist,2018

4. Pathological findings of COVID-19 associated with acute respiratory distress syndrome;Xu;Lancet Respir Med,2020

5. Effective treatment of severe COVID-19 patients with tocilizumab;Xu;Proc Natl Acad Sci USA,2020

Cited by 238 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The usage of immunosuppressant agents and secondary infections in patients with COVID-19 in the intensive care unit: a retrospective study;Scientific Reports;2024-09-09

2. A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management;Current Topics in Medicinal Chemistry;2024-08

3. ОСОБЛИВОСТІ ПРОЗАПАЛЬНИХ ЦИТОКІНІВ (IL-6 І TNF-α) У ДІТЕЙ ІЗ COVID-19;Актуальні питання педіатрії, акушерства та гінекології;2024-04-15

4. Interleukin 6 Antagonists in Severe COVID-19 Disease: Cardiovascular and Respiratory Outcomes;Protein & Peptide Letters;2024-03

5. Racial and Ethnic Disparities in COVID-19 Treatments in the United States;Journal of Racial and Ethnic Health Disparities;2024-02-26